Expression of centrosomal protein 55 in glioma tissue and the influence on glioma cell functions

Yifan Xu, Tianyu Lu, Wu Xu, Weitao Chen, Weibang Liang, Wei Jin

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, China

Contributions: (I) Conception and design: W Liang, W Jin; (II) Administrative support: Y Xu; (III) Provision of study materials or patients: W Liang, W Jin; (IV) Collection and assembly of data: Y Xu, T Lu, W Xu, W Chen; (V) Data analysis and interpretation: Y Xu, T Lu, W Xu, W Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Weibang Liang; Wei Jin. Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, China. Email: liangweibangdn@sina.com; jinwei_dn@sina.com.

Background: Centrosomal protein 55 (CEP55) protein has high expression levels in various tumors and plays important regulatory effects on cell cycle. We aimed to detect the expressions of CEP55 in glioma tissues, and to evaluate the effects on glioma cell functions and apoptosis.

Methods: Fifty fresh astrocytoma tissue samples resected from surgeries were collected, and twenty normal brain tissue samples were obtained as a control group. CEP55 protein expressions were measured by Western blot and immunohistochemical assay. After siRNA interference, the proliferation, migration, invasion and apoptosis of glioma cell lines LN229/T98G were detected by MTT assay, scratch assay, Transwell assay and flow cytometry respectively.

Results: The expression level of CEP55 protein in glioma tissue was significantly higher than that in normal control group, and the expressions in glioma tissues were elevated with increasing grade. Glioma cell lines in which CEP55 expression was stably knocked down were successfully constructed. MTT assay showed that the growth of these cells was significantly slowed down compared with that of normal cells. Scratch assay exhibited that their migration capability significantly decreased. Transwell assay revealed that the invasive ability was also attenuated with decreasing CEP55 expression. Flow cytometry showed that down-regulated expression of CEP55 promoted the apoptosis of LN229/T98G cells.

Conclusions: CEP55 expression increased in glioma tissues. After interference of its expression, glioma cell functions were significantly weakened, and apoptosis was facilitated. CEP55 may be a molecular marker for glioma diagnosis or a new target for molecular therapy.

Keywords: Glioma; centrosomal protein 55 (CEP55); proliferation; migration; apoptosis

Submitted Sep 16, 2018. Accepted for publication Jan 08, 2019.
doi: 10.21037/tcr.2019.01.33

View this article at: http://dx.doi.org/10.21037/tcr.2019.01.33

Introduction

Glioma originates from glial cells of the human nervous system, as a primary brain tumor with the highest incidence rate in humans to date (1). In China, the morbidity rate of glioma is about 10–20/100,000, and its incidence rate accounts for about 1–3% of those of systemic malignant tumors and approximately 46% of those of intracranial tumors (2). According to epidemiological studies, the median survival time of low-grade (WHO grade II) gliomas is 6–8 years, and those of high-grade (WHO grades III and IV) gliomas are only 3 years and 1 year respectively (3). At present, glioma is mainly treated through surgical resection plus postoperative radiotherapy or chemotherapy. Many new therapies for glioma have been developed, including postoperative combination chemotherapy with bevacizumab and lomustine (4), as well as postoperative stereotaxic radiological technique and high-dose radiotherapy for elderly patients with glioblastoma (5). However, these
therapies can only prolong the survival of patients instead of targeting gliomas. Therefore, basic research on glioma is of great significance.

The centrosome is a non-membranous organelle as well as a crucial microtubule-organizing center in cells. It is located in the periphery of the nucleus, with a diameter of about 1–2 μm, playing pivotal roles in cell cycle and mobility. The formation of centrosomal microtubule nucleus and the anchoring action of microtubules regulate their number, stability, polarity and spatial arrangement in cells, and also dominantly maintain cell morphology and material transport. Centrosomal abnormalities may lead to dysfunction of the spindle apparatus during division and appearance of genomes with aneuploidy. These aneuploid cells and unstable genomes are closely related to the onset of malignant tumors. Meanwhile, various regulatory proteins associated with centrosomes also accumulate therein along with their maturation. Their abnormal expressions cause abnormal replication of the centrosome, directly affect microtubule tissue, induce spindle apparatus disorders and mediate the progression of cell cycle (6). Centrosomal protein 55 (CEP55) is a centrosome-related protein. Fabbro et al. (7) found that CEP55 coupled to centrosomes and intermediates, and regulated the cell cycle after being phosphorylated by ERK2 and CDK1 simultaneously. The mechanism of action was proposed by Doxsey (8). CEP55 is first phosphorylated by ERK2 and CDK1 on scaffold proteins Pent B and CG-Nap, then released into the cytoplasm and rephosphorylated from PLK1 to be fully activated, finally regulating the cell cycle. Besides, Fabbro et al. (7) reported that CEP55 gene was silenced by siRNA, using HeLa cells treated with GFP-siRNA as negative control. With elapsed time, the expression level of CEP55 was lower than that of control cells, accompanied by abnormalities of multinuclear cells and appearance of metaphase spindles (more than 2). Many cells were arrested in the intermediate phase and cytokinesis failed. Collectively, CEP55 plays key regulatory roles in spindle apparatus assembly, polarization, separation and cytokinesis. In the last decade, the roles of CEP55 in breast cancer, stomach cancer, bladder cancer, etc. have been extensively studied (9-11). Nevertheless, the influence of CEP55 on glioma still lacks systematic research. Thereby motivated, we herein detected the expressions of CEP55 in glioma tissues, and assessed the effects on glioma cell functions and apoptosis.

Methods

**Glioma tissues and cells**

Fifty fresh astrocytoma tissue samples resected in our hospital from May 2016 to May 2017 were collected. There were 32 males and 18 females aged 38–64 years old, with a median age of (53.5±7.6). They were diagnosed according to the WHO 2016 Classification of Gliomas. There were 26 cases of WHO grade II, 16 cases of WHO grade III and 8 cases of WHO grade IV. All patients were not treated with radiotherapy or chemotherapy before surgery, and all samples collected from surgeries were pathologically diagnosed to have astrocytomas. Meanwhile, twenty normal brain tissue samples, which were resected from patients with severe brain traumas receiving emergency decompression surgeries, were collected as a control group. This study has been approved by the ethics committee of our hospital (approval number: NJ20161209YS).

Glioma cell lines LN229, T98G, U87, U251 and HEB were purchased from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences.

**Immunohistochemical assay**

Fresh glioma tissue and normal control tissue samples were immediately fixed in 4% paraformaldehyde solution for 15–20 min, sectioned, embedded with paraffin, bake-dried in a 60 °C incubator for 1 h to be stuck onto a glass slide, soaked in xylene solution for 10 min twice, and hydrated with gradient concentrations of ethanol solutions (100% for 5 min, 95% for 5 min, 90% for 5 min, 85% for 5 min and 75% for 5 min). Afterwards, the sections were soaked in tap water for 3 min and then in PBS for 5 min, heated in 0.01 M boiling citrate solution by microwave for 5 min, cooled for 5 min and heated again for 5 min. After being cooled down to room temperature, the sections were rinsed with double-distilled water twice, incubated with PBS in a 37 °C humidified box for 10 min, sectioned, embedded with paraffin, bake-dried in a 60 °C incubator for 1 h to be stuck onto a glass slide, soaked in xylene solution for 10 min twice, and hydrated with gradient concentrations of ethanol solutions (100% for 5 min, 95% for 5 min, 90% for 5 min, 85% for 5 min and 75% for 5 min). Afterwards, the sections were soaked in tap water for 3 min and then in PBS for 5 min, heated in 0.01 M boiling citrate solution by microwave for 5 min, cooled for 5 min and heated again for 5 min. After being cooled down to room temperature, the sections were rinsed with double-distilled water twice, incubated with PBS in a 37 °C humidified box for 10 min, rinsed three times with PBS (5 min each time), blocked with goat serum at 37 °C for 10 min, incubated with diluted primary antibody (1:500) at 4 °C overnight, washed three times with PBS (5 min each time), incubated with diluted biotinylated secondary antibody at 37 °C for 20 min, washed three times with PBS (5 min each time), incubated with diluted horseradish peroxidase-labeled streptavidin tertiary antibody at 37 °C for 20 min, and washed three times with PBS (5 min
each time). Then freshly prepared 50 μL of DAB color development solution was dropped onto the sections for 3 min of reaction. The sections were thereafter washed with tap water for 4 min, counterstained with hematoxylin for 2 min, dehydrated with gradient concentrations of ethanol solutions, transparentized with xylene, mounted with neutral resin and observed under a light microscope. The cells with clear brownish yellow particles in the cytoplasm or nucleus were determined as positive. Ten high-power visual fields were randomly selected for each section. Percentage of positive cells to total ones: <10%, negative tissue expression; ≥10%, positive tissue expression.

**Cell culture**

All cells were cultured in a 37 °C incubator with 5% CO₂. LN229, U87 and HEB cells were cultured in DMEM containing 10% fetal bovine serum (FBS), streptomycin (100 μg/mL) and penicillin (100 U/mL). T98G cells were cultured in MEM containing 10% FBS, streptomycin (100 μg/mL), penicillin (100 U/mL), 1% non-essential amino acids and 1 mM sodium pyruvate.

**Cell transfection**

Cells in the logarithmic growth phase were seeded into six-well plates at the density of 5×10⁵ per well, and 2 mL of pre-warmed complete medium was added into each well. After 24 h of inoculation, the confluence reached about 50–60%. Then 5 μL of Lipofectamine 2000 was added into 200 μL of serum-free DMEM or MEM, gently mixed, and left still for 5 min at room temperature. Subsequently, 100 pmol siRNA was added into 200 μL of serum-free DMEM or MEM, and gently mixed. The diluted siRNA and Lipofectamine 2000 were gently mixed, and placed at room temperature for 20 min to form a siRNA/Lipofectamine 2000 complex. Then 400 μL of solution containing the siRNA/Lipofectamine 2000 complex was added into the wells containing cells and 1,600 μL of complete medium, gently shaken and mixed. After the cells were incubated for 24–48 h in a CO₂ incubator at 37 °C, other experimental procedures after transfection were continued. siRNA CEP55: F: 3’-TTUUUAGAAACCAUGAAGACC-5’; R: 3’-TTGGUCUUCAUGGUUUCUAAA-5’. siRNA NC: F: 3’-TTUGCACUGUGCAAGGCCUCUU-5’; R: 3’-TTAAGAGGCUUGCACAGUGCA-5’. They were synthesized by Shanghai GenePharma Co., Ltd. (China).

**Western blot**

Cells were collected through digestion and centrifugation, resuspended by using RIPA (50 mM pH 7.5 Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS), ultrasonicated, and centrifuged at 12,000 rpm and 4 °C for 10 min. Then 50 μg of each sample was submitted to SDS-PAGE, and the products were electronically transferred to a nitrocellulose membrane. Afterwards, the membrane was blocked with 5% skimmed milk at room temperature for 1 h, incubated with primary antibody at 4 °C overnight, rinsed, and incubated with secondary antibody at 37 °C for 1 h. Scanning was conducted after ECL development. The relative expression of protein was corrected by that of internal reference and analyzed by Quantity One software.

**Real-time PCR**

Cells were collected through digestion and centrifugation, from which mRNA was extracted according to the instructions of mRNA extraction kit. The expression of CEP55 mRNA was detected by TaqMan mRNA detection kit, and real-time PCR data were analyzed using SYBR green II fluorescent staining and IQ5TM real-time PCR detection system (Bio-Rad, USA). The results were corrected by U6 RNA internal reference. The relative expression of CEP55 mRNA was expressed by 2^{-∆∆Ct}, and three independent experiments were performed.

**MTT assay**

Cells were digested and resuspended into 5×10⁴/mL using corresponding culture medium. The cell suspension was seeded into 96-well plates at 100 μL/well, placed in a 37 °C incubator with 5% CO₂, and added MTT (5 mg/mL, 20 μL/well) at 0, 12, 24, 48, 72 h respectively for 4 h of incubation. Then culture medium in the well was removed, and the cells were added 150 μL/well of DMSO and fully mixed to detect the absorbance at 570 nm by a microplate reader.

Survival rate (%) = A570_{experimental group}/A570_{control group} × 100%.

**Scratch assay**

Five equidistant lines were drawn first on the back of each well of six-well culture plate, with each line running through the entire well. Each well was inoculated with 5×10⁵ cells. After 24 h of culture, the confluence reached 70%. Then
2 mL of fresh complete medium was added into each well, and the cells were cultured in a 37 °C incubator for 24 h until the confluence reached 90%. After the original complete medium was discarded, a line perpendicular to the back of the well was drawn using a 10 μL tip. The cells were rinsed twice with PBS, 3 mL each time. Then 2 mL of serum-free complete medium was added into each well. The culture plate was placed in a 37 °C incubator, taken out at 0 and 24 h respectively, and placed under a microscope to observe cell migration. The changes of migration areas at the same time were calculated by ImageJ software.

Transwell assay

BD Matrigel and serum-free DMEM were diluted in a ratio of 5:1 and gently mixed. Subsequently, 100 μL of the mixture was added into the upper layer of each Transwell chamber and incubated for 4–6 h in a 37 °C incubator until Matrigel solidified. After digestion, the cells were centrifuged, resuspended in pre-warmed serum-free medium and counted. The Transwell chamber was washed three times with PBS and added the resuspended cell suspension at 100 μL per well. Complete medium containing 20% FBS was added into wells of the lower layer of culture plate. The cells were thereafter cultured in a 37 °C incubator for 12–24 h. The Transwell chamber was taken out, with the outer layer washed three times by PBS. Afterwards, the chamber was fixed in 95% ethanol solution for 10 min, and then washed by PBS. Then 0.05% crystal violet was added into each well for 10 min of staining. Subsequently, the cells were washed three times with PBS. Matrigel and the cells in the upper layer of Transwell chamber were thereafter gently wiped off with a cotton swab. The chamber was observed under an inverted microscope to count the number of cells penetrating the membrane.

Flow cytometry

Cells were digested, counted and then inoculated into a six-well plate. After 48 h of culture, the medium was discarded, and the cells were washed with PBS, digested with trypsin and resuspended with PBS. According to the instructions of annexin V kit, the cells were suspended with 500 μL of binding buffer, and then 5 μL of annexin V-FITC and 5 μL of propidium iodide were mixed for 15 min of reaction in dark at room temperature. The apoptosis was detected by flow cytometry.

Statistical analysis

All data were analyzed by SPSS19.0 software and expressed as mean ± standard deviation. Inter-group comparisons were performed by the t-test. The categorical data were subjected to the χ² test. All images were analyzed by ImageJ software. P<0.05 was considered statistically significant.

Results

High expression of CEP55 in glioma tissue

We first used Western blot to detect the expression of CEP55 protein in different grades of glioma tissues and normal brain tissues, and observed the expression by immunohistochemical staining. The expression of CEP55 protein in glioma tissues was significantly higher than that in the normal control group (P<0.05). Meanwhile, CEP55 protein expressions in different grades of gliomas also differed. The difference was not statistically significant between grade II and III gliomas, but statistically significant between grade II and IV gliomas and between grade III and grade IV gliomas (P<0.05) (Figure 1). The same results were obtained by immunohistochemical assay. In the normal
control group, CEP55 protein was weakly positively stained, whereas in glioma tissues, CEP55 protein staining was strongly positive, mainly around the nucleus and cytoplasm (Figure 2).

**CEP55 expressions in different cell lines**

We detected the expressions of CEP55 protein in human glioblastoma cell line HEB and glioma cell lines LN229, T98G, U87 and U251 by Western blot. The expression level of CEP55 protein in human glial cells was low, but those in glioma cell lines increased to various degrees (Figure 3). Moreover, the expression level of CEP55 protein in HEB cells was significantly different from those of glioma cells.

**Cell transfection with siRNA for CEP55 gene expression interference**

LN229 and T98G cell lines with high CEP55 protein expressions were transfected with siRNA CEP55 and siRNA NC interference fragments. The interference of CEP55 protein expression was detected by Western blot. The expression of CEP55 protein significantly decreased in the siRNA CEP55 group, which was significantly different from those of the negative control group and blank group (P<0.05), suggesting that cell lines stably silencing CEP55 had been successfully constructed (Figure 4). Consistently, RT-PCR showed that CEP55 mRNA significantly decreased in the siRNA CEP55 group, with significant difference from those of the negative control group and blank group (P<0.001) (Figure 5).

**Effects of CEP55 on cell proliferation**

Normal LN229/T98G cells, siRNA CEP55 LN229/T98G cells and siRNA NC LN229/T98G cells were seeded at the...
same density in six-well culture plates. The proliferation ability was detected by MTT assay at 0, 12, 24, 48 and 72 h after inoculation. The proliferation curve of normal LN229/T98G cells was basically the same as that of siRNA NC LN229/T98G cells, whereas siRNA CEP55 LN229/T98G cells grew significantly slower than normal LN229/T98G cells and siRNA NC LN229/T98G cells did at 24, 48 and 72 h (P<0.05) (Figure 6).

**Effects of CEP55 on cell migration**

Normal LN229/T98G cells, siRNA CEP55 LN229/T98G cells, and siRNA NC LN229/T98G cells were seeded at the same density in six-well culture plates. A cell-free
zone was drawn using a 10 μL pipette tip. The cells that were exfoliated after scratching were taken with PBS and photographed. After 24 h of culture, photographs were taken to observe the migration ability. After normal LN229/T98G cells and siRNA NC LN229/T98G cells were cultured for 24 h, the scratch area changed greatly, and the migration was fast. However, the migration area of siRNA CEP55 LN229/T98G cells did not change much, and the migration was significantly slower than those of normal LN229/T98G cells and siRNA NC LN229/T98G cells (P<0.001) (Figure 7).

Figure 6 Cell proliferation detected by MTT assay.

Figure 7 Effects of CEP55 on cell migration evaluated by scratch assay. **, Compared with LN229 group, P<0.001; ###, compared with siRNA group, P<0.001. Magnification: 200×. CEP55, centrosomal protein 5.
Effects of CEP55 on cell invasion

Normal LN229/T98G cells, siRNA CEP55 LN229/T98G cells and siRNA NC LN229/T98G cells at the same number were seeded in Matrigel-containing Transwell chambers, cultured under the same conditions for about 18 h, and then stained with crystal violet. The cells penetrating the chamber membrane were counted in the visual field at the same magnification. The invasive abilities of normal LN229/T98G cells and siRNA NC LN229/T98G cells were basically the same, but that of siRNA CEP55 LN229/T98G cells significantly reduced (P<0.001) (Figure 8).

Effects of CEP55 on cell apoptosis

Flow cytometry exhibited that the early apoptosis rate of siRNA CEP55 LN229/T98G cells significantly exceeded those of normal LN229/T98G and siRNA NC LN229/T98G cells (P<0.001) (Figure 9).

Discussion

Glioma remains a world-class problem that plagues neurosurgery. Its onset and progression are caused by many factors, and the underlying mechanism is still unclear (12). In recent years, with the development of molecular biology, epigenetics, immunology and detection methods, more coding and non-coding genes have been closely related to gliomas, paving the way for early screening of glioma, biological immunotherapy and prognosis evaluation. Although a large number of glioma suppressor genes have been discovered so far, including coding genes p15, p21, p53, Rb, PTEM (13) and non-coding genes H19, CRNDE, miRNA-16 (14), it is still mainly treated by surgical resection and postoperative radiotherapy and chemotherapy, also with unsatisfactory prognosis (15).

As an important regulatory protein in the pericentriolar material, CEP55 dominantly participates in the assembly of cell spindles and the cleavage function of cytoplasm. CEP55 gene, composed of 464 amino acids, is located on a gene sequence of human chromosome 10q23.33 containing 9 exons (7). CEP55 can couple its C-terminus with microtubule-aggregation-related protein CG-Nap and Pent B, and regulate γ-tubulin by multiple phosphorylation sites. Thus, although CEP55 is not a protein essential for microtubule aggregation or spindle assembly, it can be mediated through a variety of proteins (16). When CEP55 protein is abnormally expressed, it can cause central structural and functional abnormalities that are common in tumor cells, indicating that CEP55 may be related with tumor occurrence (17). When the expression of CCEP55 is knocked down, the probability of cytoplasmic division failure is increased, rendering most cells unable to undergo cytokinesis, which
may be one of the causes for apoptosis (18).

The expression of CEP55 is significantly higher in tissues of bladder transitional cell carcinoma than in benign prostatic hyperplasia tissues, being associated with various clinical and pathological characteristics (11). Tao et al. reported that CEP55 was highly expressed in human gastric cancer tissues and cells, also affecting cell proliferation (9). The same phenomenon has been observed in breast cancer (10). Moreover, the high expression of CEP55 has been closely related to the invasiveness and prognosis of ovarian epithelial cancer (19). In this study, Western blotting and immunohistochemical staining verified that the expression of CEP55 in glioma tissues was significantly higher than that of normal brain tissues, which was also raised with increasing WHO grade. Likewise, immunohistochemical staining suggested that the expression level of CEP55 protein may be associated with the grade of glioma. CEP55 protein also had different expression levels in different cell lines. Normal glial cells had significantly lower expression levels of CEP55 protein than those of glioma cells. Furthermore, the protein expression differences between different glioma cell lines may be ascribed to cell source and degree of malignancy. After CEP55 gene was knocked down, the proliferative, migration and invasion abilities of glioma cells were significantly lower than those of normal cells, accompanied by significantly facilitated apoptosis. Therefore, decreased expression of CEP55 can significantly inhibit the function of glioma cells and increases their apoptosis.

**Conclusions**

In summary, the expression of CEP55 increased in glioma tissue, and interfering with its expression significantly weakened cell functions and promoted apoptosis. Hence, CEP55 is a potential molecular marker for diagnosing gliomas or a new target for molecular therapy.

**Acknowledgements**

Funding: This study was financially supported by National Natural Science Foundation of China (General Program No. 81571192).

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The study was approved by the ethics
committee of our hospital (No. NJ20161209YS).

References
